Table 2 |
|||||
|
Developmental genes undergoing most striking ownregulation following exposure to dexamethasone |
|||||
|
Accession |
Gene |
SLR 30 |
SLR 60 |
SLR 120 |
SLR 240 |
|
|
|||||
|
BF001670 |
EFNB2 |
0.0 |
-0.1 |
-0.2 |
-1.3 |
|
NM_006350.2 |
FST |
-0.2 |
-0.3 |
-0.7 |
-1.2 |
|
NM_005585.1 |
MADH6 |
0.2 |
-0.2 |
-0.4 |
-1.1 |
|
NM_001546.1 |
ID4 |
0.3 |
0.1 |
-0.6 |
-1.0 |
|
NM _013409.1 |
FST |
-0.2 |
-0.1 |
-0.3 |
-0.9 |
|
U16797.1 |
EFNB2 |
-0.2 |
-0.2 |
-0.7 |
-0.9 |
|
NM_005924.1 |
MEOX2 |
0.3 |
-0.2 |
0.0 |
-0.9 |
|
NM_000346.1 |
SOX9 |
-0.1 |
0.0 |
-0.5 |
-0.8 |
|
U41813.1 |
HOXA9 |
0.0 |
-0.7 |
-0.8 |
-0.8 |
|
S69738.1 |
CCL2 |
0.4 |
0.6 |
0.3 |
-0.8 |
|
U58111.1 |
VEGFC |
-0.1 |
0.1 |
-0.2 |
-0.8 |
|
NM_018951.1 |
HOXA10 |
0.1 |
-0.3 |
-0.5 |
-0.7 |
|
NM_002166.1 |
ID2 |
0.4 |
0.0 |
-0.4 |
-0.7 |
|
NM_000600.1 |
IL6 |
0.2 |
0.0 |
-0.9 |
-0.6 |
|
AF022375.1 |
VEGF |
0.1 |
0.2 |
-0.4 |
-0.6 |
|
AI246769 |
HOXA9 |
-0.1 |
-0.6 |
-0.7 |
-0.6 |
|
D13889.1 |
ID1 |
0.2 |
0.4 |
0.0 |
-0.6 |
|
NM_002006.1 |
FGF2 |
0.1 |
-0.3 |
-0.6 |
-0.6 |
|
NM_018951.1 |
HOXA10 |
0.0 |
-0.3 |
-0.3 |
-0.6 |
|
NM_003633.1 |
ENC1 |
0.0 |
0.0 |
-0.1 |
-0.6 |
|
AI333651 |
FZD7 |
0.1 |
-0.2 |
-0.1 |
-0.6 |
|
NM_001290.1 |
LDB2 |
0.1 |
0.1 |
-0.1 |
-0.4 |
|
NM_002309.2 |
LIF |
-0.1 |
0.2 |
-0.2 |
-0.4 |
|
NM_002506.1 |
NGFB |
-0.1 |
-0.1 |
-0.7 |
-0.4 |
|
NM_005095.1 |
ZNF262 |
0.0 |
0.1 |
0.3 |
-0.4 |
|
NM_001356.2 |
DDX3 |
0.1 |
-0.1 |
-0.2 |
-0.4 |
|
NM_020249.1 |
ADAMTS9 |
-0.4 |
-0.3 |
-0.1 |
-0.4 |
|
AI968085 |
WNT5A |
0.1 |
-0.1 |
0.2 |
-0.4 |
|
AI819238 |
ID2 |
0.0 |
-0.4 |
-0.5 |
-0.4 |
|
U16153.1 |
ID4 |
0.2 |
-0.1 |
-0.5 |
-0.4 |
|
AI967981 |
ZNF45 |
0.0 |
-0.1 |
0.0 |
-0.4 |
|
U54826.1 |
MADH1 |
-0.1 |
0.0 |
-0.1 |
-0.4 |
|
NM_002167.1 |
ID3 |
0.2 |
0.0 |
-0.1 |
-0.4 |
|
NM_004333.1 |
BRAF |
-0.4 |
-0.4 |
-0.3 |
-0.4 |
|
NM_005574.2 |
LMO2 |
0.0 |
-0.1 |
-0.4 |
-0.3 |
|
R61374 |
HEY1 |
-0.4 |
-0.2 |
-0.1 |
-0.3 |
|
M27968.1 |
FGF2 |
0.1 |
-0.1 |
-0.5 |
-0.3 |
|
NM_014240.1 |
LIMD1 |
-0.3 |
-0.2 |
-0.5 |
-0.3 |
|
L37882.1 |
FZD2 |
0.1 |
-0.2 |
-0.6 |
-0.2 |
|
|
|||||
|
(SLI of ≥ 5 and a SLR ≤ -0.4 and ≥ +0.4 in one or more time points compared to control (T1) |
|||||
|
Hurson et al. BMC Musculoskeletal Disorders 2007 8:12 doi:10.1186/1471-2474-8-12 |
|||||